資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.lib.ncu.edu.tw/handle/987654321/102762
|
| 題名: | Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients |
| 作者: | 李興中;Chen, Hong-Hwa;Chen, William Tzu-Liang;Lee, Hsin-Chung;Lin, Jen-Kou;Fang, Chuan-Yin;Chou, Yenn-Hwei;Lin, Peng-Chan;Lin, Bo-Wen;Huang, Chi-Chou;Yeh, Chung-Hung;Hsu, Hsi-Hsien;Chen, Hung-Chang;Ting, Wen-Chien;Yang, Ming-Chin;Tan, Elise Chia-Hui |
| 貢獻者: | 生醫理工學院生醫科學與工程學系 |
| 關鍵詞: | Adjuvants;Adult;Aged;Antimetabolites, Antineoplastic - economics;Antimetabolites, Antineoplastic - therapeutic use;Antineoplastic Combined Chemotherapy Protocols - economics;Antineoplastic Combined Chemotherapy Protocols - therapeutic use;Cancer therapies;Capecitabine;Chemotherapy;Chemotherapy, Adjuvant;CLINICAL AND POLICY APPLICATIONS;Clinical outcomes;Colorectal cancer;Colorectal Neoplasms - drug therapy;Colorectal Neoplasms - pathology;Colorectal surgery;Cost analysis;Cost-Benefit Analysis;Deoxycytidine - analogs & derivatives;Deoxycytidine - economics;Deoxycytidine - therapeutic use;Female;Fluorouracil - analogs & derivatives;Fluorouracil - economics;Fluorouracil - therapeutic use;Health insurance;Health Status;Hospitals;Humans;Leucovorin - economics;Leucovorin - therapeutic use;Male;Medical prognosis;Medicine;Medicine & Public Health;Middle Aged;Mortality;National health insurance;Oncology;Patients;Population;Prospective Studies;Public Health;Quality of Life;Quality of Life Research;Sociology;Studies;Surveys and Questionnaires |
| 日期: | 2015-02-01 |
| 上傳時間: | 2026-04-23 11:16:15 (UTC+8) |
| 出版者: | Springer Netherlands;Cham: Springer |
| 摘要: | 摘要： Purpose The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabinebased therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients. Methods We conducted a prospective, open-label, observational, multicenter study from July 2008 to July 2011. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires was used to assess HRQoL before, during, and after treatment. The direct and indirect costs of adjuvant treatment were estimated from a specially prepared questionnaire, the National Health Insurance Research Database, and other published sources. We used propensity scoring to match samples between groups and performed multivariate analyses to adjust for differences in patient demographics and clinical characteristics. Results A total of 497 patients were enrolled, and 356 completed the surveys. Following propensity score matching, 239 patients were included in the analysis (122 in the capecitabine-based group, 117 in the 5-FU/LV-based group). Global HRQoL scores did not differ significantly between the two groups. However, compared to patients in the 5-FU/LV-based group, patients in the capecitabine-based group had less nausea and vomiting (mid-term, P = 0.024; final, P = 0.013), appetite loss (mid-term, P< 0.0001; final, P = 0.001), and fewer side effects from chemotherapy (mid-term, P = 0.017). In addition, the monthly cost of capecitabine-based therapy was lower than those of 5-FU/ LV-based therapy [NT$31,895.46 (US$1063.18) vs. NT$79,159.24 (US$2638.64) per patient]. Conclusions Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer.
其他題名： Qual Life Res
出版者： Cham: Springer
出版日期： 2015-02-01
出處： Quality of life research, 2015-02, Vol.24 (2), p.473-484
資源來源： JSTOR Arts and Sciences VII
版權： Springer International Publishing 2015
版權： Springer International Publishing Switzerland 2014
版權： Springer International Publishing Switzerland 2015
識別號： ISSN: 0962-9343
識別號： ISSN: 1573-2649
識別號： EISSN: 1573-2649
識別號： DOI: 10.1007/s11136-014-0773-x
識別號： PMID: 25099199 |
| 顯示於類別: | [生醫科學與工程學系] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 14 | 檢視/開啟 |
|
在NCUIR中所有的資料項目都受到原著作權保護.
|
